Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
Would you add pembrolizumab to enfortumab to further treat a patient with metastatic bladder cancer that progressed on avelumab maintenance after cis/gem?
Related Questions
Would you give immunotherapy after neoadjuvant gem-cis for bladder cancer if cystectomy is being postponed for months due to non-autoimmune/unrelated comorbidities?
In patients with localized small cell bladder cancer, would you consider consolidation with durvalumab after neoadjuvant chemotherapy followed by definitive local therapy (cystectomy or RT)?
Based on the results of the BladderPath trial, are you considering multiparametric bladder MRI for all patients with suspected bladder cancer diagnosis prior to TURBT, or for select patients only?
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
For neoadjuvant treatment of muscle invasive bladder cancer, are you utilizing durvalumab plus gemcitabine cisplatin over dose dense or accelerated MVAC?
In patients with muscle-invasive bladder cancer seeking bladder preservation, would positive ctDNA affect your approach to trimodality therapy?
Based on NIAGARA data, do you now feel more comfortable offering cisplatin based chemotherapy to patients with impaired renal function?
How do you interpret NIAGARA efficacy given that adjuvant nivolumab was not administered in the comparator arm?
How do you manage dysgeusia from Enfortumab Vedotin?
Do you plan to extrapolate from the NIAGARA trial regarding peri-operative durvalumab/cis/gem to treat upper tract urothelial carcinoma?
